Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

Articles by Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

Novel Therapies: R2-GDP-GOTEL and Smart Start

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Novel Treatment Combinations for R/R DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Relapsed/Refractory DLBCL: Unmet Needs

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Emerging Treatments for Relapsed/Refractory DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

SADAL Trial Regimen FDA Approval

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

SADAL Trial Overview

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

CAR T-Cell Therapy Clinical Trials

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

CAR T-Cell Therapy Response Rates

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

CAR T Cell Therapy in Relapsed/Refractory DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Relapsed/Refractory DLBCL Treatment Landscape

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

R/R DLBCL: Transplant Eligibility and R-CHOP

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Newly Diagnosed DLBCL: Treatment Decision Factors

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

DLBCL Risk Assessment and Genetic Signatures

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Therapy Initiation Prior to Cytogenetic Testing Results

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Dr. Monk on the Significance of Bevacizumab in Cervical Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology

May 7th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the FDA approval of bevacizumab and other novel agents in cervical cancer.

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

Articles by Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

Novel Therapies: R2-GDP-GOTEL and Smart Start

Novel Treatment Combinations for R/R DLBCL

Relapsed/Refractory DLBCL: Unmet Needs

Emerging Treatments for Relapsed/Refractory DLBCL

SADAL Trial Regimen FDA Approval

SADAL Trial Overview

CAR T-Cell Therapy Clinical Trials

CAR T-Cell Therapy Response Rates

CAR T Cell Therapy in Relapsed/Refractory DLBCL

Relapsed/Refractory DLBCL Treatment Landscape

R/R DLBCL: Transplant Eligibility and R-CHOP

Newly Diagnosed DLBCL: Treatment Decision Factors

DLBCL Risk Assessment and Genetic Signatures

Therapy Initiation Prior to Cytogenetic Testing Results

Dr. Monk on the Significance of Bevacizumab in Cervical Cancer

Trending on OncLive

Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC

Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer

CAR T-Cell Engineering Produces Early Efficacy Signals in Glioblastoma

Dr Cerchione on the FDA Approval of Subcutaneous Isatuximab in Myeloma

Bexobrutideg Aims to Overcome Resistance Mutations in R/R CLL